Chimerix, Inc. (CMRX) Social Stream

Featured Post From StockTwits About CMRX

$CMRX Upcoming Catalysts:

BARDA contract for TEMBEXA (Smallpox) by Year End. We're talking $80M-$100M per year. It's a virtual certainty. Mandated by government statute.

Registrational Cohort Readout in 4Q21 for ONC201 in Recurrent H3 K27M-Mutant Glioma. Needs an ORR of at least 20% with relevant duration to be Clinically Meaningful. Early results look good (n=30, ORR=30%, mPFS over 15 months). Fast Track, Orphan Drug, Rare Pediatric Disease, Peak Sales ~$500M.